• PHL10 ASSESSING PATIENT PREFERENCES AND QUALITY-ADJUSTED LIFE YEARS (QALY) OF PROPHYLACTIC HAEMOPHILIA TREATMENT

    Nov 1, 2003, 00:00

  • PRP2 HELIOX IN THE TREATMENT OF STATUS ASTHMATICUS IN THE ICU- A COSTEFFECTIVENESS ANALYSIS

    Nov 1, 2003, 00:00

  • PDB16 COST-EFFECTIVENESS OF BLOOD PRESSURE AND URINARY ALBUMIN CONTROL IN DIABETICS WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER- PHARMACOECONOMIC ANALYSIS OF THE MARVAL TRIAL-THE CASE OF GERMANY

    Nov 1, 2003, 00:00

  • PDB9 THE COMPACT-STUDY- PIOGLITAZONE VS. INSULIN FOR TREATMENT OF PATIENTS WITH TYPE-2-DIABETES MELLITUS-A MEDICAL AND PHARMACOECONOMIC ANALYSIS

    Nov 1, 2003, 00:00

  • MS4 THE IMPACT OF HEALTH CARE ATTITUDES ON PATIENT REPORTED OUTCOMES (PROS)

    Nov 1, 2003, 00:00

  • PUK11 SURVIVAL IN END-STAGE RENAL DISEASE (ESRD) PATIENTS- ECONOMIC CONSEQUENCES OF THE LACK OF AUTOLOGOUS ARTERIOVENOUS FISTULAE (AVF) AT THE START OF HEMODIALYSIS

    Nov 1, 2003, 00:00

  • PAE15 A MULTI-CENTER RETROSPECTIVE STUDY OF RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH GLAUCOMA MANAGEMENT IN FRANCE AND SWEDEN

    Nov 1, 2003, 00:00

  • PMD28 CHALLENGES FOR MODEL-BASED ECONOMIC EVALUATIONS OF GLAUCOMA AND OCULAR HYPERTENSION TREATMENTS

    Nov 1, 2003, 00:00

  • PMD25 THE TIME INCONSISTENCY OF DECISIONS IN PHARMACOECONOMIC SEQUENTIAL DECISION PROBLEMS

    Nov 1, 2003, 00:00

  • MD4 STOCHASTIC ANALYSIS OF AN RANDOMIZED CONTROLLED TRIAL IN REHABILITATION OF LOW BACK PATIENTS- REPRESENTATION OF UNCERTAINTY WHEN EFFECT DIFFERENCE IS SMALL

    Nov 1, 2003, 00:00

  • PUK1 THE USE OF A URINARY CATHETER REMINDER TO REDUCE URINARY CATHETERIZATION IN HOSPITALIZED PATIENTS

    Nov 1, 2003, 00:00

  • PMD8 PREDICTORS OF ANTIBIOTIC PRESCRIBING FOR UPPER RESPIRATORY INFECTIONS IN AN AMBULATORY POPULATION

    Nov 1, 2003, 00:00

  • PAE12 TREATMENT DURATION AS A COST DRIVER OF GLAUCOMA CARE- A LIFE-LONG SOCIETAL PERSPECTIVE IN FRANCE, GERMANY AND THE NETHERLAND

    Nov 1, 2003, 00:00

  • QL3 ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE

    Nov 1, 2003, 00:00

  • PMD18 INDIRECT COSTS OF A LARGE-SCALE IMMUNIZATION PROGRAM-WHEN COSTS EXCEED SAVINGS

    Nov 1, 2003, 00:00

  • PAR18 COST-EFFECTIVENESS ANALYSIS OF DIFFERENT DRUG THERAPIES FOR OSTEOPOROSIS

    Nov 1, 2003, 00:00

  • PRP9 INPATIENT MANAGEMENT OF ASTHMA IN CHILDREN AND ADOLESCENTS- HOSPITAL RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00

  • PMD40 UTILISATION OF THE FOCUS GROUP TECHNIQUE IN THE DEVELOPMENT OF QUALITY OF LIFE QUESTIONNAIRES

    Nov 1, 2003, 00:00

  • PAR12 ADAPTATION OF THE RAQOL FOR ESTONIA

    Nov 1, 2003, 00:00

  • PCV15 LOW GOAL ATTAINMENT IN COMMON DAILY PRACTICE AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE NETHERLANDS-THE REALITY-PHARMO STUDY

    Nov 1, 2003, 00:00

  • VV5 ASTHMA TREATMENT PREFERENCE STUDY-A CONJOINT ANALYSIS OF PREFERRED DRUG TREATMENTS

    Nov 1, 2003, 00:00

  • PCV58 ECONOMIC IMPACT OF SELECTED FIXEDCOMBINATION ANGIOTENSIN-CONVERTING ENZYME INHIBITOR/CALCIUM CHANNEL BLOCKER ANTI-HYPERTENSIVES AMONG PATIENTS WITH DIABETES

    Nov 1, 2003, 00:00

  • PSN4 ECONOMIC EVALUATION OF TACROLIMUS OINTMENT VERSUS CURRENT CARE IN MODERATE TO SEVERE ATOPIC DERMATITIS

    Nov 1, 2003, 00:00

  • PAR4 ETANERCEPT VERSUS INFLIXIMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS- A COST-EFFECTIVENESS ANALYSIS FROM THE ITALIAN NHS PERSPECTIVE

    Nov 1, 2003, 00:00

  • PMH17 HEALTH-RELATED QUALITY OF LIFE IN OUTPATIENTS WITH SCHIZOPHRENIA IN SINGAPORE

    Nov 1, 2003, 00:00

  • GD1 COST-UTILITY ANALYSIS OF RABEPRAZOLE AND ESOMEPRAZOLE FOR SYMPTOMATIC GASTRO OESOPHAGEAL REFLUX DISEASE

    Nov 1, 2003, 00:00

  • PMD37 RECOMMENDATIONS TO THE EUROPEAN REGULATORS FOR THE CROSS-CULTURAL ADAPTATION OF PRO MEASURES

    Nov 1, 2003, 00:00

  • PNM22 SOCIO-ECONOMIC IMPACT OF PARKINSONS DISEASE ON SPOUSES- THE COMPAS STUDY

    Nov 1, 2003, 00:00

  • PCN5 REPORT ON RETROSPECTIVE ANALYSIS OF HEALTH CARE COSTS OF BONE FRACTURES IN WOMEN WITH EARLY STAGE BREAST CANCER

    Nov 1, 2003, 00:00

  • PNM10 COST EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATELY SEVERE AND SEVERE ALZHEIMERS DISEASE IN SPAIN

    Nov 1, 2003, 00:00

  • PMD14 WILLINGNESS TO PAY, WILLINGNESS TO WAIT, AND SUPER QALYS- NARROWING THE CONCEPTUAL GAP BETWEEN CARDINAL AND ORDINAL HEALTH UTILITY MEASURES

    Nov 1, 2003, 00:00

  • PAE14 COST-EFFECTIVENESS ANALYSIS OF PMMA, SILICONE, AND ACRYLIC INTRA-OCULAR LENSES IN CATARACT THERAPY IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PMH4 2-YEAR OUTCOMES OF RISPERDAL CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC- RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA

    Nov 1, 2003, 00:00

  • PHP2 AIDS AND ECONOMIC GROWTH- THE EPIDEMIC TRAP, THEORY AND CALIBRATION

    Nov 1, 2003, 00:00

  • PGS6 COST EFFECTIVENESS OF CONTINUOUS AND ON-DEMAND THERAPY WITH ESOMEPRAZOLE 20MG IN PATIENTS WITH SYMPTOMATIC GASTROESOPHGEAL REFLUX DISEASE (GERD)- THE ONE STUDY

    Nov 1, 2003, 00:00

  • PUK15 VALIDATION STUDY OF THE SPANISH VERSION OF THE ICIQ-SHORT FORM. A USEFUL INSTRUMENT IN DETECTING URINARY INCONTINENCE

    Nov 1, 2003, 00:00

  • PHP28 COST-BENEFIT ANALYSIS OF A STATE POISON CENTER

    Nov 1, 2003, 00:00

  • PMH9 THE SOCIO-ECONOMIC BURDEN OF BIPOLAR DISORDER IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PMH25 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN CLINICAL TRIALS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2003, 00:00

  • CV6 AN ECONOMIC EVALUATION OF CLOPIDOGREL VS.ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISK ATHEROTHROMBOTIC PATIENTS

    Nov 1, 2003, 00:00

  • PSN7 TREATMENT OF PSORIASIS WITH CONVENTIONAL SYSTEMIC AGENTS IS ASSOCIATED WITH HIGH MEDICAL COSTS AND FREQUENT TREATMENT FAILURE

    Nov 1, 2003, 00:00

  • ME3 ESTIMATING COST-EFFECTIVENESS IN THE ABSENCE OF HEAD-TO-HEAD CLINICAL TRIALS-EXAMPLES OF TWO RECENT TECHNOLOGY ASSESSMENTS FOR NICE

    Nov 1, 2003, 00:00

  • PGS7 COST ANALYSIS OF A NEW PROPOSAL FOR REIMBURSEMENT OF PROTON PUMP INHIBITOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN BELGIUM

    Nov 1, 2003, 00:00

  • PIN33 COST-EFFECTIVENESS OF DIFFERENT TREATMENT STRATEGIES WITH INTRAPARTUM ANTIBIOTIC PROPHYLAXIS TO PREVENT EARLY-ONSET GROUP B STREPTOCOCCAL DISEASE

    Nov 1, 2003, 00:00

  • PMD7 DATA ACQUISITION AND INTEGRATION FOR ANTIBIOTIC TREATMENT REPORTING

    Nov 1, 2003, 00:00

  • PSN1 DERMATOLOGICAL DISEASES AND PODIATRIC DISORDERS IN THE FEET OF THE ELDERLY POPULATION-A DESCRIPTIVE STUDY

    Nov 1, 2003, 00:00

  • PCV32 COSTS OF HOSPITALIZATION IN DEPARTMENT OF CARDIOLOGY FOR PATIENTS WITH SYSTOLIC HEART FAILURE IN FRANCE

    Nov 1, 2003, 00:00

  • DB4 TYPE OF DIABETES AND ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG)

    Nov 1, 2003, 00:00

  • PNM18 COST-EFFECTIVENESS OF Z DRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) VERSUS BENZODIAZEPINES FOR THE SHORT-TERM MANAGEMENT OF INSOMNIA- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2003, 00:00

  • PMD1 PROPERLY ADDRESSING TIME-DEPENDENCE WHEN ANALYZING THE IMPACT OF COMPLIANCE WITH MEDICATION IN CHRONIC ILLNESSES

    Nov 1, 2003, 00:00

  • PUK10 A COST ANALYSIS OF ALFUZOSIN IN THE MANAGEMENT OF ACUTE URINARY RETENTION

    Nov 1, 2003, 00:00

  • PAR16 AN ASSESSMENT OF THE ECONOMIC BURDEN OF BENZODIAZEPINE-ASSOCIATED HOSPITAL TREATED FALL INJURIES IN THE EUROPEAN UNION

    Nov 1, 2003, 00:00

  • PSN9 PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM INFLAMMATORY DERMATITIS (PSORIASIS, ECZEMA, ATOPIC DERMATITIS AND URTICARIA) IN FRANCE-INSTANT STUDY

    Nov 1, 2003, 00:00

  • PCV44 PHARMACOECONOMIC EVALUATION OF VASOTEC IN HYPERTENSIVE PATIENTS WITH CONGESTIVE HEART FAILURE- AN UPDATE OF THE RETROSPECTIVE CANADIAN ANALYSIS BASED ON THE STUDIES OF LEFT VENTRICULAR DYSFUNCTION (SOLVD)

    Nov 1, 2003, 00:00

  • CP4 LONG-TERM PERSISTENCE WITH STATIN THERAPY IN DAILY MEDICAL PRACTICE

    Nov 1, 2003, 00:00

  • PUK3 TREATMENTS RECEIVED FOR STRESS URINARY INCONTINENCE (SUI) SYMPTOMS BY PATIENTS SEEKING HELP WITHIN A UK PRIMARY CARE SETTING

    Nov 1, 2003, 00:00

  • PIN22 MODELLING THE COST-EFFECTIVENESS OF THE VARICELLA VACCINE IN PORTUGAL

    Nov 1, 2003, 00:00

  • PCV48 LONG-TERM COST-EFFECTIVENESS OF INVASIVE STRATEGY IN PATIENT WITH UNSTABLE CORONARY ARTERY DISEASE-RESULTS FROM THE FRISC-II TRIAL

    Nov 1, 2003, 00:00

  • PCV75 PROJECTED LIFE YEAR GAINED AND OTHER BENEFITS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT ATTAINING TOTAL CHOLESTEROL GOAL WITH STATIN MONOTHERAPY IN FINLAND

    Nov 1, 2003, 00:00

  • PDB11 THE ECONOMIC CONSEQUENCES OF DIABETES TYPE 2 IN POLAND

    Nov 1, 2003, 00:00

  • PNM9 TIME SPENT AND COST ON INFORMAL CARE GIVING FOR PERSONS WITH ALZHEIMER IN SPAIN

    Nov 1, 2003, 00:00

  • PGS12 IMPACT ON WORK PRODUCTIVITY OF UPPER GASTROINTESTINAL SYMPTOMS ASSOCIATED WITH CHRONIC NSAID THERAPY IN A SWEDISH STUDY POPULATION

    Nov 1, 2003, 00:00

  • VV7 WILLINGNESS TO PAY FOR HEARING AIDS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PDB21 A COST-UTILITY ANALYSIS OF INSULIN GLARGINE (LANTUS) IN THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES

    Nov 1, 2003, 00:00

  • PCN4 ANALYSIS ON COST DIFFERENCE BETWEEN DAILY FILGRASTIM AND ONCE PER CYCLE PEGFILGRASTIM FOR PROPHYLAXIS AGAINST CHEMOTHERAPY-INDUCED NEUTROPENIA IN FRANCE AND GERMANY

    Nov 1, 2003, 00:00

  • PWH7 A NEW INSTRUMENT TO MEASURE THE PSYCHOLOGICAL IMPACT OF ERECTILE DYSFUNCTION. VALIDATION OF A SPANISH VERSION OF THE JOHNSON AND MCCOYS SELF-CONFIDENCE SCALE

    Nov 1, 2003, 00:00

  • PAR3 EVALUATING THE IMPACT OF REIMBURSEMENT OF NON SELECTIVE COX2 INHIBITORS ON TOTAL DISPENSING OF SELECTED NSAID AND SELECTED DRUGS FOR ACID RELATED DISORDERS

    Nov 1, 2003, 00:00

  • PCV27 COST-EFFECTIVENESS ANALYSIS OF ANTITHROMBOTIC TREATMENT WITH CLOPIDOGREL IN PATIENTS WITH MYOCARDIAL INFARCTION, STROKE, AND PERIPHERAL ARTERIAL DISEASE IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PCV23 ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)- A EUROPEAN OVERVIEW

    Nov 1, 2003, 00:00

  • PCN20 PEGFILGRASTIM IS PREFERRED TO FILGRASTIM IN CANCER PATIENTS ON MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT REGIMENS

    Nov 1, 2003, 00:00

  • PMH11 PRODUCTION LOSSES IN BORDERLINE PERSONALITY DISORDER- SHORTCOMINGS IN THE STANDARD METHODS OF VALUATION

    Nov 1, 2003, 00:00

  • PAE16 PSYCHOMETRIC VALIDATION OF THE NEI-VFQ 25 FRENCH VERSION IN A POPULATION OF PATIENTS TREATED FOR OCULAR HYPERTENSION AND GLAUCOMA

    Nov 1, 2003, 00:00

  • PIN41 DEVELOPMENT OF THE HERPES OUTBREAK IMPACT QUESTIONNAIRE (HOIQ)

    Nov 1, 2003, 00:00

  • PCV72 COST-EFFECTIVENESS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PDB20 THE IMPACT OF DIABETES TYPE 2 ON QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PNM25 DRUG PERSISTENCE PATTERNS SIMILAR FOR RIVASTIGMINE-TREATED PATIENTS AND DONEPEZIL-TREATED PATIENTS

    Nov 1, 2003, 00:00

  • PMD24 FIRST EXPERIENCES WITH THE CONDUCTION OF RAPID HEALTH ECONOMIC HEALTH TECHNOLOGY ASSESSMENTS

    Nov 1, 2003, 00:00

  • PIN42 MEASURING TREATMENT-SPECIFIC ASPECTS OF HRQL IN PATIENTS SUFFERING FROM PRIMARY ANTIBODY DEFICIENCIES

    Nov 1, 2003, 00:00

  • PCV24 THE MAHLER STUDY- DIFFERENCES IN RESOURCE USE FOR THE MANAGEMENT OF CHRONIC HEART FAILURE ACROSS 6 EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PNM26 STANDARD GAMBLE TECHNIQUE-A TOOL TO ASSESS QUALITY OF LIFE IN PATIENTS WITH EPILEPSY

    Nov 1, 2003, 00:00

  • PNM19 RESOURCE UTILISATION AND COSTS OF PATIENTS WITH SPINAL CORD INJURY (SCI) AFTER INITIAL REHABILITATION

    Nov 1, 2003, 00:00

  • PCV56 ESTABLISHING THE COST-EFFECTIVENESS OF STATINS IN THE PRIMARY PREVENTION OF CHD USING A QUASI MARKOV MODEL

    Nov 1, 2003, 00:00

  • PPN5 ASSESSING PATIENT SATISFACTION WITH PHARMACOLOGICAL PAIN TREATMENT IN AMBULATORY PRIMARY CARE PATIENTS

    Nov 1, 2003, 00:00

  • PCV49 COST-EFFECTIVENESS ANALYSIS OF CITICOLINE VS CONVENTIONAL TREATMENT IN STROKE PATIENTS

    Nov 1, 2003, 00:00

  • PCN10 COSTS OF MANAGING TOXICITIES IN ADVANCED NON-SMALL CELL LUNG CANCER WITH PEMETREXED COMPARED WITH DOCETAXEL AS SECOND-LINE CHEMOTHERAPY

    Nov 1, 2003, 00:00

  • PAR8 AVERAGE DAILY DOSE AND COSTS OF REIMBURSED COX-2 INHIBITORS FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN NORWAY

    Nov 1, 2003, 00:00

  • PIN5 REGIONAL ANTIBIOTIC PRESCRIBING GUIDELINE ADHERENCE RESULTS

    Nov 1, 2003, 00:00

  • PNM27 FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS (FAMS)- EVALUATING THE LINGUISTIC VALIDITY OF 5 NEW LANGUAGES- PORTUGUESE, JAPANESE, HEBREW, RUSSIAN, AND KOREAN

    Nov 1, 2003, 00:00

  • PIN34 COST-EFFECTIVENESS OF TWO SCREENING STRATEGIES FOR CHLAMYDIA TRACHOMATIS INFECTIONS IN FRANCE

    Nov 1, 2003, 00:00

  • PPN1 TOPIRAMATE FOR THE TREATMENT OF PERIPHERAL DIABETIC NEUROPATHY- CANADIAN CLINICAL EXPERIENCE

    Nov 1, 2003, 00:00

  • PDB7 THE IMPACT ON GLYCEMIC CONTROL OF DIABETIC PATIENTS BY A HOSPITAL PHARMACIST-MANAGED COMPLICANCE CLINIC IN HONG KONG

    Nov 1, 2003, 00:00

  • PHP5 HOW PHARMACOECONOMICS INDICATORS FOR THERAPEUTIC INNOVATIONS IN ACUTE AND CHRONIC DISEASE CAN ASSIST PAYORS IN THE DECISION MAKING PROCESS

    Nov 1, 2003, 00:00

  • CV10 COST-EFFECTIVENESS OF LOVASTATIN, CHOLESTYRAMINE AND GEMFIBROZIL FOR THE PRIMARY PREVENTION OF CORONARY HEART DISEASE THROUGH CHOLESTEROL REDUCTION IN CATALONIA, SPAIN

    Nov 1, 2003, 00:00

  • PDB8 AN ANALYSIS OF THE RELATIONSHIP BETWEEN RAPID TRANSITION TO INSULIN, AREA UNDER THE CURVE FOR HBA1C MEASURES ACROSS TIME AND DIABETESRELATED COMPLICATIONS- A GERMANY POPULATION BASED STUDY

    Nov 1, 2003, 00:00

  • PCV13 A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES COMPARING READMISSION RATES AND MORTALITY IN PATIENTS WITH HEART FAILURE

    Nov 1, 2003, 00:00

  • Disclosure Information

    Nov 1, 2003, 00:00

  • PMD46 PROCESS UTILITY DERIVED FROM PROVIDING INFORMAL CARE

    Nov 1, 2003, 00:00

  • PCV6 ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN ESSENTIAL HYPERTENSION IN SLOVAK REPUBLIC

    Nov 1, 2003, 00:00

  • QL1 HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN AN EVIDENCE-BASED ASTHMA DISEASE MANAGEMENT PROGRAM

    Nov 1, 2003, 00:00

  • Author Index, Volume 6

    Nov 1, 2003, 00:00

  • PNM17 RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORT AND BOTOX IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM-COST CONSIDERATIONS FOR THE REAL DOSE STUDY

    Nov 1, 2003, 00:00

  • PHP22 AN INVESTIGATION OF GENERIC DRUG UTILISATION AND POTENTIAL SAVINGS FROM GENERIC SUBSTITUTION IN THE IRISH HEALTH CARE SETTING

    Nov 1, 2003, 00:00

  • PMD2 DISABILITY IN STROKE OUTCOMES RESEARCH- CLINICAL MEANING OF THE BARTHEL INDEX, THE FUNCTIONAL INDEPENDENCE MEASURE AND THE MODIFIED RANKIN SCALE

    Nov 1, 2003, 00:00

  • VV3 HOW STABLE ARE SOCIAL PREFERENCE WEIGHTS FOR EQ-5D- RESULTS FROM A PA RTIAL REPLICATION STUDY

    Nov 1, 2003, 00:00

  • PNM3 A COST EFFECTIVENESS ANALYSIS OF ZOLMITRIPTAN NASAL SPRAY

    Nov 1, 2003, 00:00

  • PMD47 CALCULATING UTILITY VALUES FROM SF-36- A COMPARISON OF DIFFERENT ALGORITHMS

    Nov 1, 2003, 00:00

  • PHL1 HEMOGLOBIN LEVELS ASSOCIATED WITH DIAGNOSIS OF ANEMIA

    Nov 1, 2003, 00:00

  • CV2 THE ECONOMIC BURDEN OF STROKE IN SPAIN

    Nov 1, 2003, 00:00

  • PIN23 SPANISH HEALTH INTERVENTIONS FOR CHRONIC HEPATITIS B AND THEIR ASSOCIATED COSTS

    Nov 1, 2003, 00:00

  • PHP36 A MULTIDIMENSIONAL HEALTH CARE INTERVENTION APPRAISAL- THE COORDINATED PALLIATIVE CARE NETWORK 'QUIETUDE'

    Nov 1, 2003, 00:00

  • PUK9 ECONOMICAL IMPACT OF SACRAL NERVE STIMULATION THERAPY IN 62 PATIENTS WITH LOWER URINARY TRACT DYSFUNCTION

    Nov 1, 2003, 00:00

  • PMD43 BENEFITS OF TRANSLATABILITY ASSESSMENT TO ENHANCE THE COHERENCE OF DATA IN INTERNATIONAL STUDIES-THE IQOD EXPERIENCE

    Nov 1, 2003, 00:00

  • PNM6 INDIRECT COSTS DUE TO MIGRAINE IN THE UNITED STATES

    Nov 1, 2003, 00:00

  • HP4 CHILDHOOD VACCINATION AGAINST VARICELLA IN FRANCE- AN ECONOMIC EVALUATION OF DIFFERENT STRATEGIES

    Nov 1, 2003, 00:00

  • PCV36 COST-EFFECTIVENESS OF EARLY THROMBOLYSIS FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION- A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2003, 00:00

  • PGS2 A RETROSPECTIVE AUDIT OF PATIENTS REDUCING PROTON PUMP INHIBITOR DOSE TO LANSOPRAZOLE 15MG

    Nov 1, 2003, 00:00

  • PMD20 THE COST-EFFECTIVENESS OF SCREENING PROGRAMS USING SINGLE AND MULTIPLE BIRTH COHORT SIMULATIONS- A COMPARISON USING A MODEL OF CERVICAL CANCER

    Nov 1, 2003, 00:00

  • PCV47 A COST-EFFECTIVENESS ANALYSIS OF TAXUSTM DRUG-ELUTING STENT IN THE UK

    Nov 1, 2003, 00:00

  • PCV54 ECONOMIC EVALUATION OF ROSUVASTATIN IN A NATURALISTIC SETTING

    Nov 1, 2003, 00:00

  • PCV20 ECONOMIC MODELLING OF ANTIPLATELET THERAPY IN THE PREVENTION OF RECURRENT STROKE

    Nov 1, 2003, 00:00

  • PPN8 SUSTAINED-RELEASE TRAMADOL IN CHRONIC PAIN TREATMENT- EFFECTIVENESS AND INFLUENCE ON QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PIN29 REDUCING INFLUENZA SYMPTOMS BY 1.5 DAYSA PROSPECTIVE RANDOMIZED TRIAL USING THE CONTINGENT VALUATION METHOD TO ELICIT PREFERENCES FOR NEURAMINIDASE INHIBITORS

    Nov 1, 2003, 00:00

  • PMH16 AN ECONOMIC EVALUATION OF ARIPIPRAZOLE VERSUS OLANZAPINE IN A SWEDISH SETTING USING OUTCOMES OF METABOLIC SYNDROME, PROJECTED DIABETES AND CORONARY HEART DISEASE

    Nov 1, 2003, 00:00

  • PHP24 THE VALUE OF BOARD OF PHARMACEUTICAL SPECIALTY CERTIFICATION- RESOURCE USE AND DECISION-MAKING

    Nov 1, 2003, 00:00

  • PNM11 IMPACT OF DEEP BRAIN STIMULATION (DBS) OF THE SUBTHALAMIC NUCLEUS (STN) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH CARE RESOURCE USE IN ADVANCED PARKINSONIAN PATIENTS

    Nov 1, 2003, 00:00

  • PMD45 OUTCOMES RESEARCH AND PHASE 1-2 PHARMACEUTICAL RISK ASSESSMENT

    Nov 1, 2003, 00:00

  • PSN20 QUALITY OF LIFE AND PSORIASIS. IMPACT OF TACALCITOL TREATMENT IN SPANISH POPULATION

    Nov 1, 2003, 00:00

  • PHP34 THE EFFECTS OF GENETIC TESTING ON THE DEMAND FOR LIFE INSURANCE

    Nov 1, 2003, 00:00

  • PRP1 EPIDEMIOLOGY OF NASAL POLYPS AND ITS RELATIONSHIP TO ASTHMA

    Nov 1, 2003, 00:00

  • PMH23 DEVELOPMENT AND ASSESSMENT OF HEALTH STATE UTILITIES FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN USING PARENT PROXY REPORT

    Nov 1, 2003, 00:00

  • PAR2 TOWARDS VALUING PREFERENCES FOR DISTRIBUTION OF HEALTH GAIN IN HIP AND KNEE DISEASE

    Nov 1, 2003, 00:00

  • PIN16 COST-EFFECTIVENESS ANALYSIS OF FUZEON ADDED TO OPTIMAL STANDARD THERAPY VS. OPTIMIZED BACKGROUND REGIMEN ALONE IN PATIENTS WITH HIV/AIDS

    Nov 1, 2003, 00:00

  • PHL9 APPLICATION OF CONJOINT ANALYSIS TO ELICIT PREFERENCES IN HEMOPHILIA CARE- THE CONAN STUDY GROUP

    Nov 1, 2003, 00:00

  • PMH15 COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE (LA-RIS) VS HALOPERIDOL DECANOATE AND ORAL OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY

    Nov 1, 2003, 00:00

  • PNM16 THE COSTS OF MULTIPLE SCLEROSIS-A CROSS-SECTIONAL PROSPECTIVE MULTICENTRE COST OF ILLNESS STUDY IN POLAND

    Nov 1, 2003, 00:00

  • PCV9 THE USE OF SHORT MESSAGES TO THE PATIENTS MOBILE PHONE AS HEALTH CARE TOOL IN HYPERTENSION- THE HTA-ALERT STUDY AND THE INFONET PROGRAM

    Nov 1, 2003, 00:00

  • PGS11 USING A COST-UTILITY ANALYSIS FOR ASSESSING SENSITIVITY IN DRUG PRICES OF ESOMEPRAZOLE VERSUS OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX OESOPHAGITIS IN THE UK

    Nov 1, 2003, 00:00

  • PMH18 ZIPRASIDONE VS OLANZAPINE- CHANGE IN CHD RISK DURING A SIX-WEEK TRIAL

    Nov 1, 2003, 00:00

  • PHP35 SMOKING CESSATION- RELEVANCE IN THE UNDER 25 GROUP

    Nov 1, 2003, 00:00

  • PCV2 NEW TECHNOLOGIES IN THE US MEDICARE- AN EXAMINATION OF STENT ADOPTION

    Nov 1, 2003, 00:00

  • PAR17 COST-EFFECTIVENESS OF QUANTITATIVE ULTRASOUND AS A TECHNIQUE FOR SCREENING AND DIAGNOSING OSTEOPOROSIS AND SUBSEQUENTLY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES

    Nov 1, 2003, 00:00

  • PWH8 DEVELOPMENT AND INITIAL TESTING OF A NEW PATIENT-REPORTED QUESTIONNAIREERECTION QUALITY SCALE

    Nov 1, 2003, 00:00

  • PIN12 THE COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS INTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND

    Nov 1, 2003, 00:00

  • PCN2 BREAST CANCER PATIENTS USE OF HEALTH CARE INFORMATION IN DECISION-MAKING AND IN COPING WITH ILLNESS- RESULTS OF A QUALITATIVE STUDY

    Nov 1, 2003, 00:00

  • PCN14 COST IMPLICATIONS OF ORAL TREATMENT OF COLORECTAL CANCER IN GERMANY

    Nov 1, 2003, 00:00

  • PHP37 USING PATIENT REPORTED OUTCOMES (PRO) DATA TO SEGMENT HEALTH CARE CONSUMERS AND UNCOVER THEIR RECEPTIVENESS TO PHARMACEUTICAL ADVERTISING

    Nov 1, 2003, 00:00

  • ME2 A USER-FRIENDLY TOOL FOR EVALUATING AND IMPROVING THE TRANSFERABILITY OF ECONOMIC EVALUATION RESULTS BETWEEN COUNTRIES

    Nov 1, 2003, 00:00

  • RX4 PATTERNS OF USE OF COXIBS AND NON-SELECTIVE NSAIDS IN THE ELDERLY POPULATION OF QUEBEC (CANADA)

    Nov 1, 2003, 00:00

  • PAE4 CONSTRUCT VALIDITY AND RELIABILITY OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ)

    Nov 1, 2003, 00:00

  • PSN10 THE USE OF DISCRETE CHOICE ANALYSIS TO ASSIST WITH THE INTERPRETATION OF QUALITY OF LIFE SCORES

    Nov 1, 2003, 00:00

  • PMH2 EVALUATION OF ANTIDEPRESSANT MEDICATION ADHERENCE IN A NOT FOR PROFIT HEALTH CARE ORGANIZATION

    Nov 1, 2003, 00:00

  • PCV62 CLINICAL AND ECONOMIC OUTCOMES OF FONDAPARINUX VS. ENOXAPARIN IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY IN SPAIN

    Nov 1, 2003, 00:00

  • PDB10 DIABETES DISEASE MANAGEMENT IS ASSOCIATED WITH PHARMACY SAVINGS IN A MANAGED CARE SETTING

    Nov 1, 2003, 00:00

  • PMD5 A METHOD FOR IDENTIFICATION OF FRONTIER PRACTICE IN DIABETES CARE

    Nov 1, 2003, 00:00

  • PUK8 SEVELAMER USE IN HYPERPHOSPHATEMIA- HEALTH AND ECONOMIC CONSEQUENCES

    Nov 1, 2003, 00:00

  • PIN24 THE COST-EFFECTIVENESS OF 23-VALENT PNEUMOCOCCAL VACCINE IN CATALONIA, SPAIN

    Nov 1, 2003, 00:00

  • PIN40 PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM HERPES LABIALIS WITH IN FRANCE-INSTANT STUDY

    Nov 1, 2003, 00:00

  • PCN13 COST-EFFECTIVENESS OF MOHSMICROGRAPHIC SURGERY VERSUS SURGICAL EXCISION FOR THE TREATMENT OF FACIAL BASAL CELL CARCINOMAS- RESULTS OF A RANDOMISED CLINICAL TRIAL

    Nov 1, 2003, 00:00

  • PHP20 MARKET SHARE AND CHARACTERISTICS OF GENERIC DRUGS IN GREECE

    Nov 1, 2003, 00:00

  • PHP30 THE IMPLICATIONS OF THE USE OF TUBE FEEDING IN THE UK SECONDARY HEALTH CARE SYSTEM

    Nov 1, 2003, 00:00

  • CS2 BURDEN OF ILLNESS OF INFLUENZA

    Nov 1, 2003, 00:00

  • PIN25 COST-EFFECTIVENESS OF A PHARMACY-BASED SCREENING FOR CHLAMYDIA TRACHOMATIS

    Nov 1, 2003, 00:00

  • PUK2 TREATMENT PERSISTENCE OF OXYBUTYNIN XL AND TOLTERODINE IR IN A REAL-WORLD CLINICAL PRACTICE SETTING- DATA FROM THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PHP13 POLICIES FOR INCLUSION OF DRUGS FOR REIMBURSEMENT BY THE PHILIPPINE HEALTH INSURANCE CORPORATION

    Nov 1, 2003, 00:00

  • PCV74 MEASURING HEALTH RELATED QUALITY OF LIFE AFTER STROKE

    Nov 1, 2003, 00:00

  • PHP11 EFFECT OF COPAY INCREASE ON COMPLIANCE- A NATURAL EXPERIMENT

    Nov 1, 2003, 00:00

  • PMD17 PROTOCOL FOR MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS

    Nov 1, 2003, 00:00

  • PCV17 COST-EFFECTIVENESS ANALYSIS OF DALTEPARIN IN PROLONGED PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS AFTER HIP ARTHROPLASTY

    Nov 1, 2003, 00:00

  • PAE17 ASSESSING THE VALUE OF LASER IN SITU KERATOMILEUSIS (LASIK) BY PATIENT REPORTED OUTCOMES

    Nov 1, 2003, 00:00

  • PAR1 TREATMENT ADHERENCE WITH TNFINHIBITORS AND METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A LARGE STATE MEDICAID PROGRAM

    Nov 1, 2003, 00:00

  • PIN10 A COST CONSEQUENCE ON CONCOMITANT DRUG USE DURING HCV THERAPY IN MANAGED CARE PATIENTS IN THE UNITED STATES

    Nov 1, 2003, 00:00

  • PAR9 PATTERNS OF USE, DOSING AND ECONOMIC IMPACT OF BIOLOGIC AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2003, 00:00

  • PMD41 THE NATURE OF THE QUALITY-ADJUSTED LIFE YEAR (QALY) CALCULATION

    Nov 1, 2003, 00:00

  • PHP32 MANAGING TECHNOLOGICAL INNOVATION IN THE HEALTH CARE SECTOR

    Nov 1, 2003, 00:00

  • MD1 A TALE OF TWO STUDIES-A COMPARISON OF ECONOMIC DATA FROM A CLINICAL TRIAL TO A CROSS-SECTIONAL DATABASE

    Nov 1, 2003, 00:00

  • PMH19 CLIENT AND STAFF INVOLVEMENT IN FORMAT DESIGN OF A HEALTH-RELATED QUALITY OF LIFE SURVEY FOR INDIVIDUALS WITH SCHIZOPHRENIA, THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEY

    Nov 1, 2003, 00:00

  • DB2 PIOGLITAZONE MONOTHERAPY IS ASSOCIATED WITH A SIGNIFICANTLY LOWER INCIDENCE OF CARDIOVASCULAR EVENTS THAN IS INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE PROPENSITY-ADJUSTED COHORT ANALYSIS

    Nov 1, 2003, 00:00

  • PHP19 CONSUMER VALUATION OF PRESCRIPTION DRUG BENEFIT PLANS

    Nov 1, 2003, 00:00

  • PUK13 COMPARISON OF THE PERFORMANCE AND DATA QUALITY OF ELECTRONIC AND PAPER DIARIES FOR BENIGN PROSTATIC HYPERPLASIA (BPH)

    Nov 1, 2003, 00:00

  • MD3 THE IMPLICATIONS OF COMBINING HETEROGENEOUS PATIENT POPULATIONS IN META-ANALYSES

    Nov 1, 2003, 00:00

  • PWH1 EFFECT OF ORAL LOW-DOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1MG AND NORESTISTERONE ACETATE 0.5MG) ON CARDIOVASCULAR RISK IN SPANISH POSTMENOPAUSAL WOMEN

    Nov 1, 2003, 00:00

  • PUK6 COST-MINIMIZATION ANALYSIS OF TENSIONFREE VAGINAL TAPE VS. OPEN BURCH COLPOSUSPENSION IN FEMALE STRESS URINARY INCONTINENCE

    Nov 1, 2003, 00:00

  • PNM1 CARE OF PARKINSONS DISEASE (EUROPA)

    Nov 1, 2003, 00:00

  • PHP6 RESEARCH 5539- COMPARISON OF ACTUAL COSTS AND DRG-BASED REIMBURSEMENT OF INTENSIVE CARE IN GERMAN ICUS

    Nov 1, 2003, 00:00

  • PHP31 PAYMENTS FOR HIGH COST NEW TECHNOLOGY DRUGS AND BIOLOGICALS IN THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM- POLICY IMPLICATIONS

    Nov 1, 2003, 00:00

  • PHP8 THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATION DATABASES (EURO NHEED) PROJECT

    Nov 1, 2003, 00:00

  • PMD38 WORST AND BEST EYE VISUAL ACUITY CONSEQUENCES ON VISION-RELATED QUALITY OF LIFE IN PATIENTS SUFFERING FROM AGE RELATED MACULAR DEGENERATION

    Nov 1, 2003, 00:00

  • PHL8 COST-EFFECTIVENESS OF PATHOGEN INACTIVATION VIA THE INTERCEPT BLOOD SYSTEM FOR PLATELETS IN SPAIN

    Nov 1, 2003, 00:00

  • PMH10 COSTS AND EFFECTS OF RISPERDAL CONSTATM IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN GERMANY

    Nov 1, 2003, 00:00

  • PRP13 COSTS OF COPD IN GERMANY-RESULTS OF A COST-OF ILLNESS STUDY

    Nov 1, 2003, 00:00

  • PHP27 THE ASSOCIATION OF RECOMMENDED SURGICAL SITE INFECTION GUIDELINES AND OTHER FACTORS WITH HOSPITAL LENGTH OF STAY (LOS) IN PATIENTS UNDERGOING DIFFERENT CLEAN OR CLEANCONTAMINATED PROCEDURES

    Nov 1, 2003, 00:00

  • CV3 PROSPECTIVE COHORT STUDY IN HIP FRACTURE- RISK AND ECONOMIC IMPACT OF VENOUS THROMBO-EMBOLIC COMPLICATIONS (VTE) IN REAL LIFE

    Nov 1, 2003, 00:00

  • PMD34 ANALYTIC CHOICES IN ECONOMIC MODELS OF TREATMENTS FOR RHEUMATOID ARTHRITIS- WHAT MAKES A DIFFERENCE?

    Nov 1, 2003, 00:00

  • PNM7 A COST-EFFECTIVENESS ANALYSIS OF ELETRIPTAN 40MG AND 80MG VERSUS SUMATRIPTAN 50MG AND 100MG IN THE ACUTE TREATMENT OF MIGRAINE

    Nov 1, 2003, 00:00

  • PNM13 ECONOMIC EVALUATION OF DATSCAN IN THE DIAGNOSIS OF PARKINSONISM

    Nov 1, 2003, 00:00

  • PCN9 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)-OUTCOMES OF PROPHYLACTIC CARE AND COSTS IN GERMAN CANCER CENTERS

    Nov 1, 2003, 00:00

  • PNM21 PIRIBEDIL IMPROVES QUALITY OF LIFE IN PATIENTS WITH PARKINSONS DISEASE IN RUSSIA

    Nov 1, 2003, 00:00

  • PIN38 COST-EFFECTIVENESS ANALYSIS OF PEGYLATED INTERFERONS COMBINED WITH RIBAVIRIN IN THE TREATMENT OF HEPATITIS C

    Nov 1, 2003, 00:00

  • PHL2 PROBABILITY OF INITIATING ERYTHROPOIETIC THERAPY

    Nov 1, 2003, 00:00

  • PMD23 IDENTIFICATION OF UNIT COSTS IN RHEUMATOID ARTHRITIS-RESEARCH APPROACH AND RESULTS

    Nov 1, 2003, 00:00

  • PCV73 DEVELOPMENT OF PATIENT-REPORTED OUTCOME MEASURES FOR PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2003, 00:00

  • PMD30 MODELLING OF PREVALENCE, COSTS AND OUTCOME OF ACID-RELATED DISORDERS USING CLAIMS DATA

    Nov 1, 2003, 00:00

  • PHP3 PERSPECTIVES AND BARRIERS IN THE DEVELOPMENT OF PHARMACOECONOMICS AND ITS APPLICATIONS IN POLANDPRELIMINARY RESULTS OF A SURVEY

    Nov 1, 2003, 00:00

  • PNM15 DO PEOPLE CONSIDER THE EFFECTS OF ILL-HEALTH ON INCOME AND LEISURE WHEN ANSWERING HEALTH-RELATED QUALITYOF-LIFE QUESTIONS?

    Nov 1, 2003, 00:00

  • PSN18 PSORIASIS- QUALITY OF LIFE ACCORDING TO GENDER

    Nov 1, 2003, 00:00

  • PHP16 SPANISH NATIONAL HEALTH SERVICE- ANALYSIS OF THE INTRODUCTION OF NEW DRUGS IN THE CLINICAL PRACTICE FROM 1996 TO 2000

    Nov 1, 2003, 00:00

  • PWH5 QUALITY OF LIFE (QOL) DIFFERENTIATION ANALYSIS IN PATIENTS UNDERGOING CONTROLLED OVARIAN STIMULATION (COS) WITH TWO DIFFERENT PREPARATIONS OF RECOMBINANT HUMAN FOLLICLESTIMULATING HORMONE (R-HFSH)

    Nov 1, 2003, 00:00

  • PUK12 COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN KIDNEY TRANSPLANTATION- COST-MINIMISATION AND COSTEFFECTIVENESS ANALYSES

    Nov 1, 2003, 00:00

  • PCV63 COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PIN18 PROJECTED CLINICAL BENEFITS AND COSTEFFECTIVENESS OF AN HPV 16/18 VACCINE

    Nov 1, 2003, 00:00

  • PMD22 EPIDEMIOLOGY AND PHARMAECONOMY OF COPD ACROSS EUROPE

    Nov 1, 2003, 00:00

  • PDB1 IMPROVED GLYCAEMIC CONTROL AND LESS HYPOGLYCAEMIA WITH INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES LEADS TO FEWER LONG-TERM COMPLICATIONS-RESULTS OF THE DIABETES MELLITUS SIMULATION MODEL

    Nov 1, 2003, 00:00

  • RX2 CHARACTERIZATION OF POLYPHARMACY ISSUES AND SUBSEQUENT INTERVENTION IN A POPULATION OF ELDERLY COMMUNITY-DWELLING INDIVIDUALS

    Nov 1, 2003, 00:00

  • PIN7 AN ANALYSIS OF IN-VITRO UROPATHOGEN SENSITIVITY DATA TO UPDATE THE GUIDELINES FOR THE EMPIRIC TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN ADULT WOMEN IN A MANAGED CARE SETTING

    Nov 1, 2003, 00:00

  • PMH21 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY- SPANISH RESULTS

    Nov 1, 2003, 00:00

  • PCV11 PREDICTIVE VALUE OF TROPONIN T LEVELS FOR HEART FAILURE AFTER UNSTABLE ANGINA OR NON ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

    Nov 1, 2003, 00:00

  • PHP9 THE IMPACT OF CHANGING REIMBURSEMENT MECHANISMS- THE CASE OF PROPHYLAXIS IN BELGIAN HOSPITALS

    Nov 1, 2003, 00:00

  • PCV80 EARLY EVOLUTION, DETERMINANTS AND PREDICTIVE POWER OF HEALTH RELATED QUALITY OF LIFE IN A MULTICENTRIC POPULATION OF PATIENTS WITH HEART FAILURE

    Nov 1, 2003, 00:00

  • PAR7 PHARMACOECONOMICS OF COX-2-SELECTIVE INHIBITORS VERSUS NON-SELECTIVE NSAIDS AND CONCOMITANT COUMARIN USE- ECONOMIC EVALUATION LINKED TO A CASECONTROL STUDY

    Nov 1, 2003, 00:00

  • PMD3 OUTCOMES OF AN INTERVENTION TO IMPROVE HOSPITAL ANTIBIOTIC PRESCRIBING- INTERRUPTED TIME SERIES ANALYSIS WITH SEGMENTED REGRESSION

    Nov 1, 2003, 00:00

  • PAE1 CHRONIC ALLERGIC RHINITIS, ECONOMICS IMPACT- FRENCH SITUATION

    Nov 1, 2003, 00:00

  • VV8 CLINICAL INCONTINENCE SCORE RELATES TO HEALTH UTILITY VALUES

    Nov 1, 2003, 00:00

  • PWH2 EFFECTIVITY AND SAFETY OF ORAL LOWDOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1MG AND NORETISTERONE 0.5MG) IN CLIMACTERIC SYMPTOMS ON SPANISH POSTMENOPAUSAL WOMEN

    Nov 1, 2003, 00:00

  • PDB6 PREVALENCE OF RENAL FAILURE IN DIABETES TYPE 2- RESULTS FROM A POPULATION STUDY AND THE BELGIAN ESRD REGISTRY

    Nov 1, 2003, 00:00

  • PMD35 A METHODOLOGICAL APPROACH TO ASSESS COST DUE TO DYING IN THE CONTEXT OF DECISION ANALYTIC MODELLING

    Nov 1, 2003, 00:00

  • PCN11 COMPARING THE PROVIDER TIME AND COSTS FOR RED BLOOD CELL TRANSFUSIONS IN ANAEMIA MANAGEMENT OF CANCER PATIENTS USING THE ACTIVITY-BASED COSTING (ABC) METHOD IN A FRENCH AND AUSTRIAN SETTING

    Nov 1, 2003, 00:00

  • PRP10 A RANDOMIZED STUDY COMPARING THREE HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN ASTHMATIC PATIENTS

    Nov 1, 2003, 00:00

  • Abstracts Index

    Nov 1, 2003, 00:00

  • PCV5 OUTCOME AND PROGNOSTIC VALUE OF TROPONIN T IN PATIENTS WITH UNSTABLE ANGINA OR NON-Q-WAVE MYOCARDIAL INFARCTION

    Nov 1, 2003, 00:00

  • PPN3 A UK MULTI-CENTRE TRIAL-BASED COSTUTILITY ANALYSIS OF SURGICAL STABILISATION OF THE SPINE VERSUS INTENSIVE REHABILITATION FOR TREATMENT OF CHRONIC LOW BACK PAIN PATIENTS

    Nov 1, 2003, 00:00

  • PPN2 TOPIRAMATE IS EFFECTIVE IN PATIENTS WITH PERIPHERAL DIABETIC NEUROPATHY FOR WHOM OTHER ANTICONVULSANTS HAVE FAILED

    Nov 1, 2003, 00:00

  • PSN8 COST-OF-ILLNESS STUDY IN PATIENTS SUFFERING FROM CHRONIC PLAQUE PSORIASIS IN GERMANY

    Nov 1, 2003, 00:00

  • PGS3 META-ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI

    Nov 1, 2003, 00:00

  • PCV71 AN ECONOMIC EVALUATION OF TREATMENTS FOR ACUTE MI IN GREECE IN ELDERLY AND LATE TREATMENT PATIENTS

    Nov 1, 2003, 00:00

  • PIN37 INTRODUCTION OF A NEW HEALTH TECHNOLOGY, POTENTIAL BEHAVIOURAL AND ORGANISATIONAL CHANGES AND POLICY IMPACT-ASSESSMENT OF NEW INFLUENZA TREATMENTS

    Nov 1, 2003, 00:00

  • PGS13 COST OF ILLNESS AND QUALITY OF LIFE OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN ITALY

    Nov 1, 2003, 00:00

  • PMH24 EARLY SUSTAINED REMISSION IN PATIENTREPORTED OUTCOMES AMONG PRIMARY CARE PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2003, 00:00

  • PMD29 A MULTI-OUTCOME DECISION MODEL FOR PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • PMD19 THE COST-EFFECTIVENESS OF TREATMENT FOR TYPE 1 DIABETES

    Nov 1, 2003, 00:00

  • PRP12 AST-PQ16-A NEW QUESTIONNAIRE FOR MEASURING QUALITY OF LIFE (QOL) OF PARENTS OF CHILDREN WITH ASTHMA

    Nov 1, 2003, 00:00

  • PIN27 COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF THE USE OF ANTIVIRALS FOR THE TREATMENT OF INFLUENZA IN HEALTHY ADULTS

    Nov 1, 2003, 00:00

  • PGS1 AN EVIDENCE-BASED APPROACH PROVIDES A QUANTITATIVE ASSESSMENT OF THE EFFICACY OF ESOMEPRAZOLE FOR HEALING OF EROSIVE ESOPHAGITIS BASED ON DISEASE SEVERITY

    Nov 1, 2003, 00:00

  • CE2 HEALTH ECONOMIC ASSESSMENT OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

    Nov 1, 2003, 00:00

  • PCV26 COST-EFFECTIVENESS OF EXTENDING PROPHYLAXIS WITH FONDAPARINUX IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY

    Nov 1, 2003, 00:00

  • PHP4 ARE THE RESULTS OF ECONOMIC EVALUATIONS GENERALIZABLE? EVIDENCE FROM STUDIES OF PHARMACEUTICALS IN WESTERN EUROPE

    Nov 1, 2003, 00:00

  • PCV37 THE ADDITIONAL TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH METOPROLOL CR/XL WILL LEAD TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM

    Nov 1, 2003, 00:00

  • PHP18 REIMBURSING OFFICE-BASED DRUG MANAGEMENT COSTS- POLICY OPTIONS

    Nov 1, 2003, 00:00

  • PCV68 A SYSTEMATIC REVIEW OF COSTEFFECTIVENESS OF STATINS IN CARDIOVASCULAR RISK MANAGEMENT

    Nov 1, 2003, 00:00

  • PMH12 ECONOMIC CONSEQUENCES OF THE ADVERSE EVENTS RELATED WITH CURRENT ANTIPSYCHOTICS

    Nov 1, 2003, 00:00

  • PCN17 COST REDUCTION IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER USING ENDOSCOPIC ULTRASONOGRAPHY WITH FINE-NEEDLE ASPIRATION

    Nov 1, 2003, 00:00

  • PCV34 COST-EFFECTIVENESS OF FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA- A DECISION ANALYSIS

    Nov 1, 2003, 00:00

  • PNM12 EARLY DECISION MAKING MODELLING IN PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • QL7 PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME IN FRANCE-INSTANT STUDY

    Nov 1, 2003, 00:00

  • PCV51 IRBESARTAN IS COST-SAVING COMPARED TO AMLODIPINE AND STANDARD BLOOD PRESSURE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN HUNGARY

    Nov 1, 2003, 00:00

  • GD2 A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC, INJECTABLE TREATMENT AND EXISTING INTERVENTIONS IN GASTRO-OESOPHAGEAL REFLUX DISEASE

    Nov 1, 2003, 00:00

  • PAE3 RESEARCH 5771- THE ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE, ENGLAND

    Nov 1, 2003, 00:00

  • PDB3 CLAIMS DATA MEASUREMENTS OF MEDICATION ADHERENCE AND METABOLIC OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES (DM2)

    Nov 1, 2003, 00:00

  • PHP12 3THE ECONOMIC IMPLICATIONS OF NONCOMPLIANCE AFTER RENAL TRANSPLANTATION

    Nov 1, 2003, 00:00

  • PHP14 DRUG PRICE INDICES 1980-2002 IN FINLAND

    Nov 1, 2003, 00:00

  • PCV3 EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE

    Nov 1, 2003, 00:00

  • CV8 CLINICAL OUTCOMES AND COSTS OF DRUG ELUTING STENTS IN THE CARDIAC CATHERIZATION LAB

    Nov 1, 2003, 00:00

  • PIN39 DIRECT COST ANALYSIS OF HEPATITIS B INFECTION IN FRANCE

    Nov 1, 2003, 00:00

  • PMD10 GENETIC TESTING, PREDICTIVE GENETIC TESTING FOR HEREDITARY CANCER

    Nov 1, 2003, 00:00

  • PCV69 THE COST-EFFECTIVENESS OF CYP2C9 GENOTYPING IN MANAGEMENT OF WARFARIN THERAPY-A DECISION TREE ANAYSIS

    Nov 1, 2003, 00:00

  • PCV59 ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY- COSTMINIMIZATION ANALYSIS BASED ON LIFE STUDY

    Nov 1, 2003, 00:00

  • PCV79 DEVELOPMENT AND VALIDATION OF THE NEW HEALTH-RELATED QUALITY OF LIFE INSTRUMENT SPECIFIC TO PATIENTS WITH CORONARY ARTERY DISEASE (CAD) IN POLAND- POL-CAD

    Nov 1, 2003, 00:00

  • PWH3 PULSED OESTROGEN THERAPY WITH INTRANASAL 17-B OESTRADIOL IMPROVES WOMENS QUALITY OF LIFE IN THE EARLY POSTMENOPAUSAL PERIOD

    Nov 1, 2003, 00:00

  • PHL4 COST OF CARE AND QUALITY OF LIFE IN HEMOPHILIACS DEVELOPING INHIBITORS AGAINST PRODUCTS OF COAGULATION- THE COCIS STUDY

    Nov 1, 2003, 00:00

  • VV4 DEVELOPING A PREFERENCE-BASED MEASURE FOR POSTMENOPAUSAL HEALTH

    Nov 1, 2003, 00:00

  • PUK5 COMPARISON OF THE DOSE AND COST OF EPREX BY ROUTE OF ADMINISTRATION

    Nov 1, 2003, 00:00

  • PCV7 MITRAL REPAIR CAN BE SAFELY PERFORMED IN CASES OF INCREASED COMPLEXITY

    Nov 1, 2003, 00:00

  • PPN9 CHRONIC PAIN PATIENTS SATISFACTION AND QUALITY OF LIFE WITH TRANSDERMAL ANALGESIC MEDICATION

    Nov 1, 2003, 00:00

  • PCV4 PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN ASIAN PATIENTS- COMPARISON OF PROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN AND INDOMETHACIN

    Nov 1, 2003, 00:00

  • HP2 THE IMPACT OF TREATMENT MANAGEMENT ALGORITHMS AND EVALUATED TIME HORIZON ON ANTIVIRAL TREATMENT COSTS IN CHRONIC HEPATITIS C

    Nov 1, 2003, 00:00

  • PIN20 THE IMPACT OF COST-EFFECTIVENESS OF COUNTRY SPECIFIC APPLICATION-THE CASE OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE SEPSIS

    Nov 1, 2003, 00:00

  • PCV41 A COST ANALYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES USING CLOPIDOGREL IN ADDITION TO ASPIRIN IN A HONG KONG PUBLIC HOSPITAL

    Nov 1, 2003, 00:00

  • PSN17 PSORIASIS AND QUALITY OF LIFE SPANISH RESULTS

    Nov 1, 2003, 00:00

  • PDB14 COST-EFFECTIVENESS ANALYSIS OF THE ACARBOSE PHARMACOLOGICAL TREATMENT AS A PREVENTIVE MEASURE OF THE DEVELOPMENT OF TYPE 2 DIABETES IN SUBJECTS DIAGNOSED OF IMPAIRED GLUCOSE TOLERANCE (IGT)

    Nov 1, 2003, 00:00

  • PMD9 OPTIMIZATION OF AIDS PILOT CLINICAL TRIAL USING LEAMSIM

    Nov 1, 2003, 00:00

  • PHP23 THE DRUG PRICE REFERENCE INDEX STUDY OF THE PHILIPPINE HEALTH INSURANCE CORPORATION

    Nov 1, 2003, 00:00

  • PCN1 AN ASSESSMENT OF THE UPDATED RESULTS FROM THE ARIMIDEX, TAMOXIFEN, ALONE OR IN COMBINATION (ATAC) TRIAL- AN EVIDENCE-BASED MEDICINE APPROACH

    Nov 1, 2003, 00:00

  • PRP4 COST-UTILITY OF BECLOMETHASONEEXTRAFINE (BDP-EF) IN PATIENTS WITH MODERATE AND SEVERE ASTHMA

    Nov 1, 2003, 00:00

  • PIN15 COST-EFFECTIVENESS ANALYSIS OF VORICONAZOLE VERSUS AMPHOTERICIN B IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN SPAIN

    Nov 1, 2003, 00:00

  • PSN19 DERMATOSIS AND DEPRESSIVE SYMPTOMATOLOGY- FRENCH RESULTS

    Nov 1, 2003, 00:00

  • CE4 COST-EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH ADVANCED AND/OR METASTATIC BREAST CANCER IN FRANCE

    Nov 1, 2003, 00:00

  • VV6 TRANSFORMING THE UNIFIED PARKINSONS DISEASE RATING SCALE INTO A UTILITY SCALE

    Nov 1, 2003, 00:00

  • PAR15 THE BURDEN OF OSTEOPOROSIS IN EUROPE- AN EPIDEMIOLOGICAL MODEL

    Nov 1, 2003, 00:00

  • PCV61 THE COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH ENOXAPARIN VERSUS SHORT-TERM PROPHYLAXIS AFTER ELECTIVE HIP REPLACEMENT IN POLAND

    Nov 1, 2003, 00:00

  • PAE2 THE BURDEN OF ALLERGIC CONJUNCTIVITIS IN THE UK- FINDINGS FROM A RETROSPECTIVE REVIEW OF THE GPRD DATABASE 1990-2000

    Nov 1, 2003, 00:00

  • PHL12 MORE PRECISE DOSING INCREMENTS OF HUMAN GROWTH HORMONE DELIVERY SYSTEMS LEAD TO COST SAVINGS IN THE UK SETTING

    Nov 1, 2003, 00:00

  • PIN14 POST-EXPOSURE INFLUENZA PROPHYLAXIS WITH OSELTAMIVIR- COST-EFFECTIVENESS AND COST-UTILITY IN FAMILIES IN THE UK

    Nov 1, 2003, 00:00

  • PHP1 POTENTIAL FINANCIAL IMPACT OF ITEM RESPONSE THEORY-BASED INDICATIONS FOR LONG-TERM HEALTH CARE FACILITIES

    Nov 1, 2003, 00:00

  • PIN35 MENINGOCOCCAL C VACCINATION OF CHILDREN AGED LESS THAN 1 YEAR- INCLUSION OF HERD IMMUNITY LEADS TO LESS FAVORABLE COST-EFFECTIVENESS RATIOS

    Nov 1, 2003, 00:00

  • PCV18 HEALTH SYSTEM COSTS OF OUT-OF-HOSPITAL CARDIAC ARREST IN RELATION TO TIME TO SHOCK

    Nov 1, 2003, 00:00

  • PHP7 PHARMACOECONOMICS IN HEALTH CAREDECISION MAKING- A SURVEY ON CHINA HEALTH CARE SYSTEM

    Nov 1, 2003, 00:00

  • PDB4 POPULATION-BASED DIABETES INTERVENTION IN A MANAGED CARE SETTING

    Nov 1, 2003, 00:00

  • PNM2 COST-EFFECTIVENESS OF ELETRIPTAN 40MG COMPARED WITH STANDARD DOSES OF AVAILABLE TRIPTANS FOR ACUTE MIGRAINE ATTACKS IN SPAIN

    Nov 1, 2003, 00:00

  • PIN30 COSTS OF PULMONARY TUBERCULOSIS IN UKRAINE

    Nov 1, 2003, 00:00

  • PIN6 INDICATORS OF ANTIBIOTIC USE IN PRIMARY HEALTH CARE OF REPUBLIC OF SRPSKA

    Nov 1, 2003, 00:00

  • PHP26 INTENSIVIST PRACTICE CHANGE IN GLUCOSE CONTROL FOR CRITICALLY ILL PATIENTS

    Nov 1, 2003, 00:00

  • PMH1 METHYLPHENIDATE FORMULATION IS ASSOCIATED WITH ACCIDENT/INJURY RATE IN CHILDREN WITH ADHD

    Nov 1, 2003, 00:00

  • PCN3 EXPERT PANEL DEPICTION OF CLINICAL PRACTICE IN THE TREATMENT OF BREAST CANCER PATIENTS IN GREECE

    Nov 1, 2003, 00:00

  • PAE13 COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES- THE UK, GERMANY AND FRANCE

    Nov 1, 2003, 00:00

  • PWH4 VASOMOTOR SYMPTOMS AND QUALITY OF LIFE (QOL) IN POSTMENOPAUSAL WOMEN

    Nov 1, 2003, 00:00

  • MH2 COST-EFFECTIVENESS OF THE HIT PROGRAMME IN PATIENTS WITH SCHIZOPHRENIA AND PERSISTENT AUDITORY HALLUCINATIONS

    Nov 1, 2003, 00:00

  • PSN12 QUALITY-OF-LIFE IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY

    Nov 1, 2003, 00:00

  • PNM4 COST-EFFECTIVENESS STUDY OF RIZATRIPTAN VS. USUAL CARE IN THE TREATMENT OF MIGRAINE IN CANADA

    Nov 1, 2003, 00:00

  • MS3 A DEMONSTRATION OF THE USE OF BAYESIAN DECISION THEORY TO OPTIMISE DRUG DEVELOPMENT PROGRAMMES

    Nov 1, 2003, 00:00

  • VV2 DESIGN AND VALIDATION OF A NEW WEB-BASED STANDARD GAMBLE INTERVIEW

    Nov 1, 2003, 00:00

  • PAE5 PREVALENCE OF LOW VISION AND BLINDNESS IN FRANCE

    Nov 1, 2003, 00:00

  • CP1 LOWER PERSISTENCE WITH ANTIHYPERTENSIVE DRUGS AMONG WOMEN COMPARED TO MEN

    Nov 1, 2003, 00:00

  • PAR11 IMPLEMENTATION STUDY OF A HEALTH EDUCATION AND EXERCISE PROGRAM FOR OSTEOARTHRITIS OF THE KNEE

    Nov 1, 2003, 00:00

  • PAR5 THE TOTAL COSTS OF TREATMENT WITH VALDECOXIB COMPARED TO GENERIC DICLOFENAC ARE SIMILAR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN GERMANY

    Nov 1, 2003, 00:00

  • PHP15 COMPARISON OF MARKET EXCLUSIVITY OF PHARMACEUTICALS IN CANADA, THE UNITED STATES, THE UNITED KINGDOM AND FRANCE

    Nov 1, 2003, 00:00

  • CS4 COST-BENEFIT ANALYSIS OF AN INTERNET-BASED PATIENT EDUCATION PROGRAMME FOR ASTHMATIC CHILDREN AND ADOLESCENTS

    Nov 1, 2003, 00:00

  • PSN11 THE WILLINGNESS-TO-PAY FOR PSORIASIS TREATMENT IN DENMARK

    Nov 1, 2003, 00:00

  • PCV46 SWITCHING PATIENTS TO ROSUVASTATIN FROM ATORVASTATIN OR OTHER STATINS IS COST-EFFECTIVE- PHARMACOECONOMIC ANALYSIS OF MERCURY I

    Nov 1, 2003, 00:00

  • CV1 A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION

    Nov 1, 2003, 00:00

  • PCN16 HEAD AND NECK CANCER COSTS IN A FRENCH PRIVATE CENTRE

    Nov 1, 2003, 00:00

  • PCV77 THE ECONOMIC ASSESSMENT OF LIPID LOWERING THERAPY WITH EZETIMIBE IN SPAIN

    Nov 1, 2003, 00:00

  • PCV55 'FAST-TRACKING' IN THE CARDIAC INTENSIVE CARE UNIT- A TRIAL-BASED ECONOMIC EVALUATION OF THREE SEDATION/ANALGESIA PROTOCOLS IN THE MANAGEMENT OF PATIENTS FOLLOWING CARDIAC SURGERY

    Nov 1, 2003, 00:00

  • PAR10 CROSS-CULTURAL ADAPTATION AND VALIDATION OF KOREAN VERSION OF EQ-5D IN PATIENTS WITH RHEUMATIC DISEASES

    Nov 1, 2003, 00:00

  • PIN28 HOSPITAL MANAGEMENT OF PERTUSSIS IN GERMANY- COST PER CASE BY AGE

    Nov 1, 2003, 00:00

  • PCV39 ECONOMIC EVALUATION OF THE MEDENOX (PROPHYLAXIS IN MEDICAL PATIENTS WITH ENOXAPARIN) TRIAL FROM THE PERSPECTIVE OF HOSPITALS IN GERMANY- RESULTS OF A SUBGROUP ANALYSIS

    Nov 1, 2003, 00:00

  • PCN6 HEALTH ECONOMIC EVALUATION OF A NEW CONTRAST PRODUCT FOR LIVER MRI IN COLORECTAL CANCER PATIENTS

    Nov 1, 2003, 00:00

  • PMD36 ARE ISPOR SHORT COURSES A COSTEFFECTIVE WAY OF EDUCATING PARTICIPANTS AND ENHANCING MEETING ATTENDANCE?

    Nov 1, 2003, 00:00

  • PIN11 ABACAVIR HYPERSENSITIVITY- IS PREPRESCRIPTION GENOTYPING COSTEFFECTIVE?

    Nov 1, 2003, 00:00

  • PGS4 ESOMEPRAZOLE AS MAINTENANCE THERAPY IN EROSIVE ESOPHAGITIS- A QUANTITATIVE ASSESSMENT OF EFFICACY USING AN EVIDENCE-BASED APPROACH

    Nov 1, 2003, 00:00

  • PUK7 DITROPAN XL VERSUS DETROL IN CANADA- ECONOMIC ANALYSIS

    Nov 1, 2003, 00:00

  • PHP29 WHERE DOES THE GERMAN HEALTH CARE SYSTEM WANT TO GO TO?

    Nov 1, 2003, 00:00

  • RX3 THE ANTIBIOTIC USE IN POLAND IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADOLESCENTS AND ADULTS VERSUS CURRENT GUIDELINES

    Nov 1, 2003, 00:00

  • PNM5 MANAGEMENT COSTS OF CHEST AND CNSRELATED ADVERSE EVENTS OF TRIPTANS (SEROTONIN 5-HT1B/1D AGONISTS) IN SPAIN

    Nov 1, 2003, 00:00

  • CV5 SHORT AND LONG TERM COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT S T-SEGMENT ELEVATION (ACS) IN SCANDINAVIAN COUNTRIES

    Nov 1, 2003, 00:00

  • PCV65 EVALUATING THE ECONOMIC VALUE OF SIROLIMUS-ELUTING STENT IN KOREA

    Nov 1, 2003, 00:00

  • PGS5 ECONOMIC BURDEN OF IRRITABLE BOWEL SYNDROME (IBS)- ONE YEAR RESULTS. RITMO STUDY

    Nov 1, 2003, 00:00

  • PRP16 COST-EFFECTIVENESS OF BUPROPION SR IN THE TREATMENT OF TOBACCO DEPENDENCE

    Nov 1, 2003, 00:00

  • PIN26 COST OF MANAGING CHRONIC HEPATITIS B IN THE UK

    Nov 1, 2003, 00:00

  • PUK4 TREATMENT OF URINARY INCONTINENCE IN DAILY PRACTICE DOES NOT COMPLY WITH THE GUIDELINES

    Nov 1, 2003, 00:00

  • PMD31 ENSURING A STANDARD USER INTERFACE FOR MODELS- MODEL-IT

    Nov 1, 2003, 00:00

  • PCN19 COST ANALYSIS OF COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIAGNOSIS OF PROSTATE CANCER

    Nov 1, 2003, 00:00

  • PDB2 IS THERE A GAIN WITH THE PAIN? ASSESSMENT OF THE RELATIONSHIP BETWEEN SELF-REPORTED ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) AND HBA1C LEVELS AMONG TYPE 2 DIABETICS

    Nov 1, 2003, 00:00

  • PRP3 LOSSES IN PRODUCTIVITY DUE TO ASTHMA- A POPULATION BASED ESTIMATE

    Nov 1, 2003, 00:00

  • PCV67 AN ECONOMIC EVALUATION OF ALTEPLASE, RETEPLASE AND TENECTEPLASE IN TREATMENT OF ACUTE MI IN GREECE

    Nov 1, 2003, 00:00

  • Incorporating the Patient's Perspective into Drug Development and Communication- An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001

    Sep 1, 2003, 00:00

  • Long-Term Resource Use and Cost of Percutaneous Transluminal Coronary Angioplasty versus Stenting in the Elderly- A Retrospective Claims Data Analysis

    Sep 1, 2003, 00:00

  • When Should Functional Neuroimaging Techniques Be Used in the Diagnosis and Management of Alzheimer's Dementia? A Decision Analysis

    Sep 1, 2003, 00:00

  • Academy of Managed Care Pharmacy Format- Relevance, Rigor, Regulation, and Realism

    Sep 1, 2003, 00:00

  • The Clinical Characteristics and Impact of Laryngopharyngeal Reflux Disease on Health-Related Quality of Life

    Sep 1, 2003, 00:00

  • A Review of Selected Patient-Generated Outcome Measures and Their Application in Clinical Trials

    Sep 1, 2003, 00:00

  • The Academy of Managed Care Pharmacy Format for Formulary Submissions- An Evolving Standard—A Foundation for Managed Care Pharmacy Task Force Report

    Sep 1, 2003, 00:00

  • Validation of Health Economic Models- The Example of EVITA

    Sep 1, 2003, 00:00

  • Observations from a Hospital Executive (Decision Maker) on the Article “Long-Term Resource Use and Cost of Percutaneous Transluminal Coronary Angioplasty versus Stenting in the Elderly- A Retrospective Claims Data Analysis”

    Sep 1, 2003, 00:00

  • The Pediatric Quality Appraisal Questionnaire- An Instrument for Evaluation of the Pediatric Health Economics Literature

    Sep 1, 2003, 00:00

  • Task Force Report of the Patient-Reported Outcomes Harmonization Group- Too Much Harmony, Not Enough Melody?

    Sep 1, 2003, 00:00

  • Medication Compliance Feedback and Monitoring in a Clinical Trial- Predictors and Outcomes

    Sep 1, 2003, 00:00

  • Methodology for Estimating Current and Future Burden of Osteoporosis in State Populations- Application to Florida in 2000 through 2025

    Sep 1, 2003, 00:00

  • Cost Implications of Administering Intravenous Proton Pump Inhibitors to All Patients Presenting to the Emergency Department with Peptic Ulcer Bleeding

    Jul 1, 2003, 00:00

  • The Impact of Including Passive Benefits in Cost-Effectiveness Analysis- The Case of Automated External Defibrillators on Commercial Aircraft

    Jul 1, 2003, 00:00

  • Assessment of Respondent Acceptability of Preference Measures- Discriminatory Power of Graphic Positioning Scale versus Traditional Scaling Measures

    Jul 1, 2003, 00:00

  • Risk Management- Issues for Outcomes Research

    Jul 1, 2003, 00:00

  • Cost-Effectiveness of Migraine Treatment- A Commentary

    Jul 1, 2003, 00:00

  • Seasonal versus Perennial Allergic Rhinitis- Drug and Medical Resource Use Patterns

    Jul 1, 2003, 00:00

  • A Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine

    Jul 1, 2003, 00:00

  • Decision Makers' Needs as Capacities to Benefit

    Jul 1, 2003, 00:00

  • Future Burden and Costs of Smoking-Related Disease in the Netherlands- A Dynamic Modeling Approach

    Jul 1, 2003, 00:00

  • Cost-Effectiveness Analysis in Health Policy

    Jul 1, 2003, 00:00

  • Do Decision Makers Really Need Health Economic Data?

    Jul 1, 2003, 00:00

  • Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit Program

    Jul 1, 2003, 00:00

  • Using Stated Preference Modeling to Forecast the Effect of Medication Attributes on Prescriptions of Alcoholism Medications

    Jul 1, 2003, 00:00

  • Use of Pharmacoeconomics Information—Report of the ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health-Care Decision Making

    Jul 1, 2003, 00:00

  • PDB19- THE COST-EFFECTIVENESS OF TARKA FOR PREVENTING RENAL FAILURE IN TYPE 2 DIABETIC PATIENTS WITH HYPERTENSION IN THE US HEALTH CARE SETTING

    May 1, 2003, 00:00

  • PRP5- COMPLIANCE WITH ASTHMA CONTROLLER MEDICATIONS- AN ANALYSIS OF GAPS IN CARE AND OPPORTUNITIES FOR COST REDUCTION

    May 1, 2003, 00:00

  • PHP3- THE EFFECT OF HOSPITAL COMPLIANCE WITH THE JOINT COMMISSION ON THE ACCREDITATION OF HEALTHCARE ORGANIZATIONS (JCAHO) PERFORMANCE MEASURES AND PUBLISHED GUIDELINES ON OUTCOMES OF PATIENTS WITH HEART FAILURE

    May 1, 2003, 00:00

  • QL4- SMOKING STATUS AND HEALTH-RELATED QUALITY OF LIFE (HRQOL)- FINDINGS FROM THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA

    May 1, 2003, 00:00

  • PAR4- ECONOMIC IMPLICATIONS OF NON-COMPLIANCE WITH OSTEOPOROSIS TREATMENT IN ACTUAL PRACTICE

    May 1, 2003, 00:00

  • PHP2 3- PRESCRIBING INCENTIVE SCHEMES- DO THEY GIVE APPROPRIATE INCENTIVES FOR COST-EFFECTIVE PRESCRIBING?

    May 1, 2003, 00:00

  • PARI I- VERIFICATION OF A DECISION ANALYTIC MODEL ASSUMPTION USING REAL WORLD PRACTICE DATA- IMPLICATIONS FORTHE COST-EFFECTIVENESS OF COX-2S

    May 1, 2003, 00:00

  • PMH18- RETROSPECTIVE DRUG USE EVALUATION OF ANTIPSYCHOTIC AGENTS IN THE VETERANS ADMINISTRATION SYSTEM-A POPULATION BASED APPROACH

    May 1, 2003, 00:00

  • PCV32- EXCESS COSTS FOR SINGLE AGENT MEDICATION TREATMENT OF HYPERTENSION- 1999 DATA FROM THE NEWYORK STATE MEDICAID CLAIMS DATABASE

    May 1, 2003, 00:00

  • PDB5- MEDICATION COMPLIANCE IN TYPE 2 DIABETES SUBJECTS- RETROSPECTIVE DATA ANALYSIS

    May 1, 2003, 00:00

  • PRK14- PERCEIVED RISK, VALUE AND QUALITY OF LIFE FOR PATIENTS WITH OVERACTIVE BLADDER- DEVELOPMENT OF A PERCEIVED VALUE SCALE

    May 1, 2003, 00:00

  • PDB3- EFFICACY OF INSULIN GLARGINE IN PATIENTS WITH TYPE 1 AND 2 DIABETES

    May 1, 2003, 00:00

  • PAR6- ECONOMIC ANALYSIS OF NOVEL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) FOR RHEUMATOID ARTHRITIS (RA) PATIENTS IN A MANAGED CARE SETTING

    May 1, 2003, 00:00

  • PMH11- DOES THE SHORT-TERM ADMINISTRATION OF A BENZODIAZEPINE IMPROVE COMPLIANCE WITH ANTIDEPRESSANT THERAPY?

    May 1, 2003, 00:00

  • PRP24- ASSESSMENT OF THE IMPROVEMENTS IN QUALITY OF LIFE POST-LUNG TRANSPLANT- A COMPARISON OF RECIPIENTS VERSUS CANDIDATES

    May 1, 2003, 00:00

  • CV3- INFLUENCE OF DIABETES AND BASELINE ST-SEGMENT CHANGE STATUS ON THE COST-EFFECTIVENESS OF AN EARLY INVASIVE VS. CONSERVATIVE STRATEGY FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES-APPLICATION OF A NET-BENEFIT REGRESSION APPROACH TO DATA ...

    May 1, 2003, 00:00

  • PNP6- THE USE OF DISEASE-ALTERING NEW DRUGS FOR MULTIPLE SCLEROSIS TREATMENT

    May 1, 2003, 00:00

  • PIN17- THE VALUE OF VACCINATING INFANTS AND CHILDREN WITH PNEUMOCOCCAL CONJUGATE VACCINE

    May 1, 2003, 00:00

  • PNP27- ASSESSING BEHAVIORAL FUNCTIONING IN ALZHEIMERS DISEASE- BENCHMARKING WITH THE BEHAVE-AD-FW

    May 1, 2003, 00:00

  • CV5- THE COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A STATE MEDICAID PROGRAM PERSPECTIVE

    May 1, 2003, 00:00

  • PHP I I- A STUDY ON SAVINGS AND HEALTH-RELATED SAVING MOTIVE IN CHINESE RESIDENTS IN HONG KONG

    May 1, 2003, 00:00

  • PCNIO- FEAR OF CANCER RECURRENCE AFTER TREATMENT FOR PROSTATE CANCER- DATA FROM CAPSURE

    May 1, 2003, 00:00

  • PDB10- A METHODOLOGY TO IDENTIFY HIGH-RISK PATIENTS WITH DIABETES IN THE CALIFORNIA MEDICAID POPULATION (MEDI-CAL)

    May 1, 2003, 00:00

  • PIN6- IMPACT OF CHANGES IN REIMBURSEMENT POLICY ON ANTIBIOTIC RESISTANCE

    May 1, 2003, 00:00

  • PHP21- REVIEWS OF UTAH MEDICAID HIGH UTILIZERS TO CONTROL DRUG COSTS

    May 1, 2003, 00:00

  • PCV2- TELEMONITORS REDUCE HOSPITAL AND ER ADMISSIONS FOR HOMEBOUND CONGESTIVE HEART FAILURE (CHF) PATIENTS

    May 1, 2003, 00:00

  • PNP29- CLINITRAC-A NOVEL METHOD FOR EVALUATING OUTCOME IN PARKINSON DISEASE

    May 1, 2003, 00:00

  • PNP12- A COST CONSEQUENCE ANALYSIS OF THE MANAGEMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN THE UK

    May 1, 2003, 00:00

  • PMD21- AN INVESTIGATION OF PATIENT HETEROGENEITY AND THE POTENTIAL FOR BIAS IN MODELLING STUDIES-AN EXAMPLE USING A MARKOV MODEL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2003, 00:00

  • PMH38- A STUDY OF THE ECONOMIC BURDEN OF DEPRESSION

    May 1, 2003, 00:00
  • «
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166 (current)
  • 167
  • 168
  • 169
  • 170
  • »